Juvenile myelomonocytic leukemia (JMML) is a rare, clonal myeloproliferative and myelodysplastic disorder that occurs in early childhood. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only known curative approach for this disease. 1 Hemophagocytic syndrome (HPS; also known as hemophagocytic lymphohistiocytosis), which is characterized by the inappropriate activation of macrophages due to uncontrolled hypercytokinemia, 2 is known to occur early (during weeks 2-6) after allo-HSCT as a rare complication. [3] [4] [5] [6] Previously, two studies used genotyping or microsatellite polymorphism analysis to show that 98-99% of the whole bone marrow nucleated cells in patients with allo-HSCT-HPS are of donor origin. 4, 6 This suggests that the activated macrophages involved in the development of HPS are of donor origin. However, it has not been demonstrated directly that this is the case. Here, we show by immunostaining and genotyping analyses that host-type macrophages are involved in two episodes of allo-HSCT-associated HPS in a JMML case.
A 2-year-old boy with JMML was transplanted with bone marrow from an HLA-full matched unrelated female donor. The conditioning regimen consisted of fludarabine (25 mg/m 2 for 4 days), busulfan (140 mg/m 2 for 4 days) and melphalan (90 mg/m 2 for 2 days). Tacrolimus and shortterm methotrexate were given as a GVHD prophylaxis. The number of infused CD34-positive cells was 1.6 Â 10 6 /kg. Both the donor and recipient were CMV seropositive. The patient developed early onset-HPS on day 39 in the postengraftment period that was characterized by high-grade fever, skin rash, leukocytopenia (o0.5 Â 10 9 /l), thrombocytopenia (o30 Â 10 9 /l), elevated aminotransferase levels, extremely high levels of ferritin (75 895 ng/ml) and vigorous hemophagocytosis in the bone marrow. The symptoms of HPS resolved following the administration of high-dose (2 g/kg) intravenous immunoglobulin (HD-IVIG). Unfortunately, the patient developed graft failure and hence received a cord blood transplant, 2 months later from an unrelated female donor following a conditioning regimen consisting of fludarabine (25 mg/m 2 for 4 days) and melphalan (70 mg/m 2 for 2 days). One dose of etoposide (100 mg/m 2 ) was added to this regimen in an attempt to suppress residual macrophage activity. Tacrolimus monotherapy was given as a GVHD prophylaxis. The number of infused CD34-positive cells was 1.0 Â 10 6 /kg. On day 6 in the pre-engraftment period after cord blood transplantation (CBT), the patient presented with high-grade fever, skin rash, decreased urine output and decreased oxygen saturation (SpO 2 95%) manifested by pulmonary infiltrates. On day 11, the patient was again diagnosed to have early onset-HPS, given laboratory findings showing markedly elevated serum ferritin levels (28 169 ng/ml) and increased hemophagocytosis in the bone marrow. PCR analysis failed to detect adenovirus, EBV, CMV or human herpes virus-6 genomes in the patient's serum. After one dose of etoposide (50 mg/m 2 ) and HD-IVIG, the symptoms of HPS subsided and durable engraftment was achieved on day 20. The patient has sustained a complete remission 4 months after CBT.
Bone marrow clot specimens that were obtained after both BMT and CBT were analyzed to elucidate the origin of the activated macrophages that probably drove the two episodes of HPS. Immunostaining was undertaken with anti-CD163 antibody to detect macrophages and these cells were then genotyped by FISH using X-or Y-chromosomespecific probes (Figure 1 ). The CD163-positive spindleshaped or large spread cells were defined as macrophages.
The frequency of hemophagocytic cells and the chimerism of the entire nucleated cell population and macrophages in the bone marrow are shown in Table 1 . At the onset of the first episode of HPS (on day 39 after BMT), genotyping revealed that 31.2% of all nucleated cells and 80% of the macrophages in the bone marrow were of host origin. However, at the onset of the second episode of HPS (on day 11 after CBT), only 0.8% of the nucleated cells in the peripheral blood (data not shown) and 16% of all nucleated cells and 70% of macrophages in the bone marrow were host type. Two weeks after treating the patient with etoposide and HD-IVIG (on day 25 after CBT), 2.2% of all nucleated cells and 60% of macrophages in the bone marrow were still host type. These results suggest that residual host-derived macrophages were involved in the development of allo-HSCT-associated HPS in this patient.
The various clinical features observed in the early phase after allo-HSCT are largely driven by complex alloresponse mechanisms (either graft-versus-host or host-versus-graft) that involve the activation of donor T cells and host epithelial cells, and the abundant secretion of proinflammatory cytokines. 7 Theoretically, these alloresponses inappropriately activate macrophages and cause HPS. However, the origin of the macrophages that manifest the hemophagocytosis observed after allo-HSCT is unclear. In this study, we found that the majority of macrophages in the bone marrow of our patient after BMT and CBT were of host origin, contrary to previous reports. 4, 6 This is supported by the observation in chronic myelogenous leukemia that the macrophage population remains chimeric until 3 months after allo-HSCT, even when myeloablative conditioning regimens (including total body irradiation) are employed. 8 We conclude that host-derived macrophages were involved in the development of the early onset-allo-HSCT-associated HPS as a form of host-versus-graft response, and that this may induce graft rejection. However, given that JMML is a myelomonocytic proliferative disease and that patients with JMML are therefore predisposed to develop HPS, 9,10 it remains possible that our observation is only pertinent for JMML. Thus, further analysis is required to confirm whether host-derived macrophages are responsible for allo-HSCT-associated HPS in general. Letter to the Editor
